Expanding Treatment in The Neoadjuvant Setting

Tuesday, November 19, 2019

Neoadjuvant chemotherapy is the standard treatment for patients with stage III lung cancer, but new studies show promise for the combination of neoadjuvant immunotherapy in these patients, before surgery.

At the 14th Annual New York Lung Cancers Symposium OncLive®, a sister publication to Oncology Nursing News®, had the chance to speak with Ashish Saxena, MD, PhD, medical oncologist at Weil Cornell Medicine, on this new avenue for treatment and what the standard treatment is for patients with stage III lung cancer.   

Generally, for patients with stage III disease, we typically do neoadjuvant chemotherapy as a standard treatment. Trials are going on, including one that we are doing at our institution of neoadjuvant immunotherapy to get a similar response in the tumor before surgery, and then to see if that translates into better overall survival for the patient. Generally, we decide treatment based on the stages and for stage three we typically do neoadjuvant therapy.

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Related Videos
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.